免疫毒素新进展:肿瘤靶向治疗与免疫治疗的结合  

New advances in immonotoxin: Combination of tumor targeted therapy and immunotherapy

作　　者：韦笑[1] 陈仿军 辛恺[1,2] 刘芹[1,2] 李琳 禹立霞[1,2] 刘宝瑞[1,2] WEI Xiao;CHEN Fangjun;XIN Kai;LIU Qin;LI Lin;YU Lixia;LIU Baorui(The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,Clinical College of Nanjing Medical University,Nanjing 210008,China)

机构地区：[1]南京医科大学鼓楼临床医学院肿瘤中心,南京210008 [2]南京大学医学院附属鼓楼医院肿瘤中心,210008

出　　处：《临床肿瘤学杂志》2019年第7期643-648,共6页Chinese Clinical Oncology

基　　金：国家重点研发计划专项经费资助项目(2017YFC1308900)

摘　　要：免疫毒素是将毒素分子连接到靶向肿瘤细胞的载体分子上形成的融合蛋白。传统免疫毒素因免疫原性强且穿透性差的特性难以取得理想的临床效果。近年来基因重组技术克服了传统免疫毒素的缺陷,使得重组免疫毒素再次发展并被用于治疗各种恶性肿瘤。但是免疫原性问题依旧存在,并与治疗效果呈负相关,所以寻找新的方法改进免疫毒素以降低免疫原性成为未来研究的重点。本文对免疫毒素当前的研究进展及未来的发展方向作一综述。Immunotoxins are chimeric proteins with a toxin moiety linked or genetically fused to a targeting moiety and can target cancer cells.The clinical applications of traditional immunotoxins are disappointing due to their high immunogenicity and poor penetrability.Nowadays genetic recombination technology has been employed to overcome the historical challenge of traditional immunotoxins,allowing recombination immunotoxins(RITs)to be developed again and applied for various malignancies.However,the issue of immunogenicity is remaining and shows a negative correlation with clinical efficacy.Thus future researches focus on developing new strategies to modify immunotoxins that reduce immunogenicity.The review summarizes the current state and progress of immunotoxins.

关 键 词：肿瘤 靶向治疗 免疫治疗 免疫毒素 重组免疫毒素 

分 类 号：R730.5[医药卫生—肿瘤]